Raymond James & Associates Sage Therapeutics, Inc. Transaction History

Raymond James & Associates

$150 Billion
Q2 2024

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 25, 2023	BUY	$40.65 - $59.54 $151,177 - $221,429	3,719 Added 38.28%	13,435 $631,000
Q1 2023 Apr 14, 2023	BUY	$37.27 - $46.57 $127,127 - $158,850	3,411 Added 54.1%	9,716 $407,000
Q4 2022 Feb 08, 2023	BUY	$32.2 - $43.61 $203,021 - $274,961	6,305 New	6,305 $240,000
Q2 2021 Aug 11, 2021	SELL	$54.88 - $79.29 $532,445 - $769,271	-9,702 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$70.65 - $96.76 $216,047 - $295,892	-3,058 Reduced 23.97%	9,702 $726,000
Q4 2020 Feb 12, 2021	SELL	$58.41 - $89.06 $4.89 Million - $7.46 Million	-83,725 Reduced 86.78%	12,760 $1.1 Million
Q3 2020 Nov 04, 2020	BUY	$41.13 - $62.45 $2.84 Million - $4.32 Million	69,147 Added 252.93%	96,485 $5.9 Million
Q2 2020 Jul 28, 2020	BUY	$25.95 - $43.15 $166,002 - $276,030	6,397 Added 30.55%	27,338 $1.14 Million
Q1 2020 Apr 21, 2020	BUY	$26.15 - $77.24 $322,455 - $952,446	12,331 Added 143.22%	20,941 $601,000
Q4 2019 Feb 12, 2020	SELL	$60.18 - $154.77 $1.6 Million - $4.12 Million	-26,648 Reduced 75.58%	8,610 $622,000
Q3 2019 Nov 07, 2019	SELL	$140.29 - $189.96 $299,238 - $405,184	-2,133 Reduced 5.7%	35,258 $4.95 Million
Q2 2019 Aug 06, 2019	BUY	$157.85 - $183.09 $676,229 - $784,357	4,284 Added 12.94%	37,391 $6.85 Million
Q1 2019 May 06, 2019	BUY	$89.33 - $163.65 $947,076 - $1.74 Million	10,602 Added 47.11%	33,107 $5.27 Million
Q4 2018 Feb 11, 2019	BUY	$81.94 - $139.71 $51,704 - $88,157	631 Added 2.88%	22,505 $2.16 Million
Q3 2018 Nov 14, 2018	BUY	$138.11 - $169.04 $461,425 - $564,762	3,341 Added 18.03%	21,874 $3.09 Million
Q2 2018 Aug 14, 2018	BUY	$140.36 - $175.76 $604,109 - $756,471	4,304 Added 30.25%	18,533 $2.9 Million
Q1 2018 May 14, 2018	SELL	$152.15 - $192.33 $53,556 - $67,700	-352 Reduced 2.41%	14,229 $2.29 Million
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $25,138 - $69,278	414 Added 2.92%	14,581 $2.4 Million
Q3 2017 Nov 13, 2017	SELL	$61.4 - $88.52 $529,943 - $764,016	-8,631 Reduced 37.86%	14,167 $883,000
Q2 2017 Aug 14, 2017	BUY	N/A	22,798	22,798 $1.82 Million

Others Institutions Holding SAGE

# of Institutions

218

Shares Held

48.2M

Call Options Held

854K

Put Options Held

195K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $395M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account